Assessment With CCTA and MRI in Asymptomatic Patients With Type 2 Diabetes for Detection of Unrecognized Myocardial Scar in Subclinical Coronary Atherosclerosis
NCT ID: NCT01254552
Last Updated: 2019-05-31
Study Results
Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.
View full resultsBasic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE4
351 participants
INTERVENTIONAL
2010-08-31
2016-10-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Carotid Intima-media Thickness (IMT) and Large-vessel Atherosclerosis by Multidetector Computed Tomography (MDCT)
NCT00949169
Impact of Cardiac Magnetic Resonance Imaging on Endothelial Function in Type 2 Diabetes
NCT02001753
Early MRI Detection of Myocardial Deterioration as a Preventive, Disease Staging, and Prognostic Biomarker in Insulin Resistance
NCT03509441
Imaging of Intracranial and Extracranial Arterial Atherosclerotic Plaques Using Different Field Strength MRIs
NCT06754956
Magnetic Resonance Angiography to Diagnose Atherosclerotic Disease
NCT00382564
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
DIAGNOSTIC
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Dotarem and Xenetix 350
iobitridol
Xenetix 350 was administered at a dose up to 180 ml, according to the patient's body weight measured on the day of administration.
gadoterate meglumine
Dotarem was administered at a dose of 0.1 mmol/kg body weight (0.2 ml/kg body weight)
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
iobitridol
Xenetix 350 was administered at a dose up to 180 ml, according to the patient's body weight measured on the day of administration.
gadoterate meglumine
Dotarem was administered at a dose of 0.1 mmol/kg body weight (0.2 ml/kg body weight)
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Patient between the ages of 50 and 75 years at enrolment time
* Patient with at least two identified cardiac risk factors who will undergo a CMR and a CCTA examinations to evaluate his/her coronary and cardiac status
Exclusion Criteria
* Patient with stress test or invasive coronary angiography within the prior 3 years
* Patient with history of myocardial infarction, overt non compensated heart failure, or coronary revascularization
* Patient with hemodynamic instability.
* Patient with a contraindication or intolerance to Beta-Blocker administration
50 Years
75 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Guerbet
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Asan Medical Center
Seoul, , South Korea
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
ISO-44-011
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.